Form D · Biotechnology
TScan Therapeutics, Inc.
Waltham, MA · CIK 0001783328
Offering snapshot reported Jan 28, 2021 · SEC filing
- Reported sold
- $100M Offering amount: $100M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 15, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 28, 2021 | Initial | $100,000,000 | No comparison | 16 | SEC filing |
| Jul 26, 2019 | Initial | $23,300,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-387638
Source: Form D, filed Jan 28, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Timothy Barberich | Director |
| Robert Crane | Executive |
| Doug Fambrough | Director |
| Lea Hachigian | Director |
| Ittai Harel | Director |
| Andrew Hedin | Director |
| Steve Kraus | Director |
| Campbell Murray | Director |
| Nandita Shangari | Director |
| Brian Silver | Director |
| Hannes Smarason | Director |
| David Southwell | Director, Executive |
| Christoph Westphal | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
830 Winter Street
Waltham, MA, 02451
Waltham, MA, 02451